| Stem definition | Drug id | CAS RN |
|---|---|---|
| calcium metabolism regulator, pharmaceutical aid | 4074 | 180064-38-4 |
None
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 0.01 % | Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K |
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 11, 2011 | PMDA |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Osteonecrosis of jaw | 78.40 | 34.28 | 27 | 991 | 35096 | 63452908 |
| Atypical femur fracture | 73.07 | 34.28 | 17 | 1001 | 5355 | 63482649 |
| Hepatic function abnormal | 51.06 | 34.28 | 20 | 998 | 37122 | 63450882 |
| Spinal compression fracture | 48.07 | 34.28 | 15 | 1003 | 14268 | 63473736 |
| Upper respiratory tract inflammation | 39.72 | 34.28 | 9 | 1009 | 2514 | 63485490 |
None
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Osteonecrosis of jaw | 84.28 | 32.42 | 31 | 1407 | 43195 | 79699755 |
| Atypical femur fracture | 66.45 | 32.42 | 16 | 1422 | 5173 | 79737777 |
| Hepatic function abnormal | 59.13 | 32.42 | 28 | 1410 | 73079 | 79669871 |
| Spinal compression fracture | 51.71 | 32.42 | 17 | 1421 | 16941 | 79726009 |
| Upper respiratory tract inflammation | 39.34 | 32.42 | 10 | 1428 | 4025 | 79738925 |
| Interstitial lung disease | 37.47 | 32.42 | 24 | 1414 | 112576 | 79630374 |
None
None
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Osteoporosis | indication | 64859006 | DOID:11476 |
None
None
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 2.11 | acidic |
| pKa2 | 6.18 | acidic |
| pKa3 | 7.16 | acidic |
| pKa4 | 10.96 | acidic |
| pKa5 | 11.56 | acidic |
| pKa6 | 5.65 | Basic |
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Farnesyl pyrophosphate synthase | Enzyme | IC50 | 8.52 | CHEMBL | |||||
| Geranylgeranyl pyrophosphate synthase | Enzyme | Ki | 5.74 | CHEMBL | |||||
| Farnesyl diphosphate synthase | Enzyme | IC50 | 5.96 | CHEMBL | |||||
| Geranylgeranyl pyrophosphate synthase | Enzyme | Ki | 6.89 | CHEMBL |
| ID | Source |
|---|---|
| D09198 | KEGG_DRUG |
| C2825721 | UMLSCUI |
| M0N | PDB_CHEM_ID |
| CHEMBL319144 | ChEMBL_ID |
| DB06548 | DRUGBANK_ID |
| 130956 | PUBCHEM_CID |
| 3164 | IUPHAR_LIGAND_ID |
| C087958 | MESH_SUPPLEMENTAL_RECORD_UI |
| 7651 | INN_ID |
| 40SGR63TGL | UNII |
None